Dasatinib Is Associated with Rapid and Durable Complete Hematologic Responses in Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML)

被引：0
|
作者：
Liu, Delong [1 ]
Matloub, Yousif [2 ]
Mulchopadhyay, Jaydip [2 ]
Liu, David [2 ]
Goldberg, Stuart L. [3 ]
机构：
[1] New York Med Coll, Valhalla, NY 10595 USA
[2] Bristol Myers Squibb Co, Wallingford, CT 06492 USA
[3] Hackensack Univ, Med Ctr, John Theurer Canc Ctr, Hackensack, NJ USA
来源：
BLOOD | 2008年 / 112卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：741 / 741
页数：1
相关论文
共 50 条
  • [1] Dasatinib Is Well-Tolerated and Efficacious in Imatinib-Intolerant Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML).
    Khoury, Hanna Jean
    Mauro, Michael J.
    Matloub, Yousif
    Chen, Tai-Tsang
    Bahceci, Erkut
    Deininger, Michael
    BLOOD, 2009, 114 (22) : 463 - 464
  • [2] Cytogenetic and Molecular Responses in Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML) in a Prospective Observational Study (SIMPLICITY)
    Mauro, Michael
    Gambacorti-Passerini, Carlo
    Goldberg, Stuart L.
    Cortes, Jorge E.
    Khoury, H. Jean
    Michallet, Mauricette
    Paquette, Ronald
    Simonsson, Bengt
    Turner, Michelle P.
    Mohamed, Hesham
    Subar, Milayna
    Zyczynski, Teresa
    BLOOD, 2014, 124 (21)
  • [3] Cytogenetic and molecular responses in German patients with chronic-phase chronic myeloid leukemia (CP-CML) in a prospective observational study (SIMPLICITY)
    Repp, R.
    Hehlmann, R.
    Linde, H.
    Reiser, M.
    Tesch, H.
    Foreman, A.
    Schreiner, L.
    Hillig, G.
    Oncology Research and Treatment, 2015, 38 : 132 - 132
  • [4] Resistance, Outcome and the Development of Mutations with Dasatinib in Patients with Chronic-Phase Chronic Myeloid Leukemia (CML-CP).
    Shah, Neil
    Bahceci, Erkut
    Lambert, Alexandre
    Ploughman, Lynn
    Radich, Jerald
    BLOOD, 2009, 114 (22) : 460 - 460
  • [5] Cardiovascular Hospitalization in Patients Treated with Dasatinib or Nilotinib in Simplicity, an Observational Study of Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients in Routine Clinical Practice
    Mauro, Michael J.
    Chen, Clara
    Cortes, Jorge E.
    Gambacorti-Passerini, Carlo
    Sen, Ginny P.
    Gajavelli, Srikanth
    Davis, Catherine
    Michallet, Mauricette
    BLOOD, 2018, 132
  • [6] Molecular Responses to Dasatinib and Nilotinib in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP)
    Quintas-Cardama, Alfonso
    Kantarjian, Hagop
    Michor, Franziska
    Olshen, Adam
    Gonen, Mithat
    Jones, Dan
    Rios, Mary Beth
    O'Brien, Susan
    Cortes, Jorge
    BLOOD, 2008, 112 (11) : 1114 - 1115
  • [7] COST-EFFECTIVENESS ANALYSIS OF PONATINIB IN THE TREATMENT OF CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA (CP-CML) IN SWEDEN
    Iannazzo, S.
    McGarry, L.
    Chiroli, S.
    VALUE IN HEALTH, 2015, 18 (07) : A668 - A668
  • [8] Four-year follow-up of patients with chronic-phase chronic myeloid leukemia (CP-CML) receiving 100 mg of dasatinib once daily
    Shah, N. P.
    Cortes, J. E.
    Schiffer, C. A.
    le Coutre, P.
    Bahceci, E.
    Lambert, A.
    Saglio, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [9] AN ECONOMIC EVALUATION OF DASATINIB (SPRYCEL®) IN CHRONIC PHASE CHRONIC MYELOID LEUKEMIA (CP-CML) IN CENTRAL AND EASTERN EUROPE
    Nagy, B.
    Kutikova, L.
    Stastny, M.
    Vasile, K.
    Nagy, Zsolnai, I
    Mayer, J.
    VALUE IN HEALTH, 2008, 11 (06) : A358 - A358
  • [10] Notch Pathway Activation Targets Leukemic Stem Cells in Chronic-Phase Chronic Myeloid Leukemia (CP-CML)
    Horne, Gillian A.
    Morrison, Heather
    Campbell, Victoria
    Kinstrie, Ross
    Cassels, Jennifer
    Hair, Alan
    Vetrie, David
    Wheadon, Helen
    Holyoake, Tessa L.
    Copland, Mhairi
    BLOOD, 2016, 128 (22)
12345